Tag
The FDA is examining expanded testosterone therapy approvals for libido while GLP-1's grip on obesity treatment faces a scientific challenge from its own pioneers. Researchers now argue GIP-glucagon dual targeting may match GLP-1 efficacy with better tolerability. Kailera Therapeutics raised $625 million in what is
A Cochrane review has intensified debate over the clinical value of amyloid-targeting Alzheimer's therapies, while the FDA moves to reconvene advisory panels on compounded peptides it had restricted. Eli Lilly plans to submit its oral GLP-1 drug Foundayo to the FDA by end of Q2 after a positive cardiovascular outcomes
PolyPeptide has drawn buyout interest as its operational turnaround gains traction with potential acquirers. The development signals improving confidence in the contract peptide manufacturer's stability, with the peptide CDMO sector under heightened strategic attention due to GLP-1 drug demand. Whether a formal sale pr
Tag
The FDA is examining expanded testosterone therapy approvals for libido while GLP-1's grip on obesity treatment faces a scientific challenge from its own pioneers. Researchers now argue GIP-glucagon dual targeting may match GLP-1 efficacy with better tolerability. Kailera Therapeutics raised $625 million in what is
2mo ago · 1 min · Business
A Cochrane review has intensified debate over the clinical value of amyloid-targeting Alzheimer's therapies, while the FDA moves to reconvene advisory panels on compounded peptides it had restricted. Eli Lilly plans to submit its oral GLP-1 drug Foundayo to the FDA by end of Q2 after a positive cardiovascular outcomes
2mo ago · 1 min · Technology
PolyPeptide has drawn buyout interest as its operational turnaround gains traction with potential acquirers. The development signals improving confidence in the contract peptide manufacturer's stability, with the peptide CDMO sector under heightened strategic attention due to GLP-1 drug demand. Whether a formal sale pr
2mo ago · 1 min · Business
— End of feed —